274 / 364
DANONE
REGISTRATION DOCUMENT 2015
Corporate Governance
6.3 Compensation and benefits of corporate officers and governance bodies
274
Impact in terms of dilution/ownership of the Company's share capital
Year ended December 31, 2009
Number of shares
Percentage of share capital
(a)
Grants during the fiscal year
Stock-options granted
2,725,011
0.4%
Of which stock-options granted to all the corporate officers
575,050
0.1%
(a) Percentage of share capital on the grant date (date of the Shareholders' Meeting authorizing the stock-option grants).
Year ended December 31
2014
2015
Number of shares
Percentage of share
capital
(a)
Number of shares
Percentage of share
capital
(a)
Balance as of December 31 (b)
Active stock-options
5,688,697
0.88%
1,345,171
0.21%
Of which stock-options granted to all
the corporate officers
1,206,810
0.19%
188,150
0.03%
(a) Percentage of share capital at December 31 of the fiscal year in question.
(b) Balance of exercisable stock-options at December 31 of the fiscal year in question.
Compensation and benefits paid to the corporate officers and governance bodies
Compensation and benefits paid to members of the Board of Directors and Executive Committee
Summary of compensation and benefits paid to members of the Board of Directors and Executive
Committee
Year ended December 31
(in € millions)
2014
2015
Compensation paid to the corporate officers and Executive
Committee members
(a)
13.4
16.5
Attendance fees paid to Directors
(b)
0.6
0.6
Compensation paid
14.0
17.1
Severance pay
2.1
–
Accounting value of Group performance shares granted
(c)
9.1
8.2
(a) Annual andmulti-annual fixed and variable compensation (gross amount excluding employer contributions), of which the variable portion totaled €8.4million
in 2015 (€7 million in 2014).
(b) The two corporate officers are not eligible to receive attendance fees.
(c) The Accounting value represents the full value estimated as of the grant date in accordance with IFRS 2 on the assumption that the performance conditions
have been satisfied (see details above and Note 7.4 of the Notes to the consolidated financial statements).